Anzeige
Mehr »
Dienstag, 12.08.2025 - Börsentäglich über 12.000 News
Diese Aktie liegt in der Turbo-Zone - und könnte der Gold-Gewinner 2025/26 werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CQ72 | ISIN: US1523091007 | Ticker-Symbol: 260
Frankfurt
12.08.25 | 15:29
13,800 Euro
-1,43 % -0,200
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
CENTESSA PHARMACEUTICALS PLC ADR Chart 1 Jahr
5-Tage-Chart
CENTESSA PHARMACEUTICALS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
14,50014,80022:58
14,50014,90022:00

Aktuelle News zur CENTESSA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:42Centessa Pharmaceuticals GAAP EPS of -$0.38 misses by $0.043
13:14Centessa Pharmaceuticals plc - 10-Q, Quarterly Report3
13:10Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025222Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type...
► Artikel lesen
13:08Centessa Pharmaceuticals plc - 8-K, Current Report3
CENTESSA PHARMACEUTICALS Aktie jetzt für 0€ handeln
21.07.Truist Securities stuft Centessa Pharmaceuticals mit "Buy" ein und sieht erhebliches Potenzial5
21.07.Truist Securities initiates Centessa Pharmaceuticals stock with Buy rating3
04.07.Nxera Pharma To Receive $4.8 Mln Milestone As Centessa Advances ORX142 To Phase 1 Study2
04.07.Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist188Tokyo, Japan and Cambridge, UK, 4 July 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals...
► Artikel lesen
17.06.Centessa Pharmaceuticals plc - 8-K, Current Report1
16.06.Centessa gets clearance to begin trial of ORX1421
16.06.Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year378BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration...
► Artikel lesen
29.05.Centessa Pharmaceuticals kündigt Änderungen in der Führungsebene an1
29.05.Centessa Pharmaceuticals plc - 8-K, Current Report2
20.05.Piper Sandler maintains Centessa stock with $38 target1
14.05.Centessa Pharmaceuticals GAAP EPS of -$0.20 beats by $0.15, revenue of $15M1
14.05.Centessa Pharmaceuticals plc - 10-Q, Quarterly Report2
14.05.Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025525Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy...
► Artikel lesen
14.05.Centessa Pharmaceuticals plc - 8-K, Current Report3
08.05.This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday2
31.03.Piper Sandler sets Centessa stock with $38 target, Overweight rating4
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1